Myriad Genetics Adds Breast Cancer Prognostic Dx to Portfolio Through Sividon Acquisition | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics announced after the close of the market Tuesday the acquisition of Sividon Diagnostics in a deal that adds a breast cancer prognostic test to Myriad's product portfolio and enhances its competitive position in oncology diagnostics.

Myriad acquired Sividon for €35 million ($39 million) upfront and up to €15 million in payments based on the product achieving future performance milestones. The company funded the deal using cash on hand.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.